Medicus Pharma Ltd (NASDAQ:MDCX) Receives $14.50 Average PT from Analysts

Medicus Pharma Ltd (NASDAQ:MDCX) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $14.50.

Several analysts have recently commented on MDCX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a research note on Friday, April 10th. Roth Mkm started coverage on shares of Medicus Pharma in a research note on Tuesday. They set a “buy” rating on the stock. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 price target on shares of Medicus Pharma in a research note on Monday.

Hedge Funds Weigh In On Medicus Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Armistice Capital LLC acquired a new stake in shares of Medicus Pharma during the fourth quarter worth $2,771,000. Yorkville Advisors Global LP acquired a new stake in shares of Medicus Pharma during the third quarter worth $532,000. Private Advisor Group LLC raised its holdings in shares of Medicus Pharma by 3.8% during the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock worth $351,000 after acquiring an additional 5,500 shares during the period. Jane Street Group LLC acquired a new stake in shares of Medicus Pharma during the fourth quarter worth $92,000. Finally, Wilmington Savings Fund Society FSB raised its holdings in shares of Medicus Pharma by 100.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after acquiring an additional 25,622 shares during the period.

Medicus Pharma Stock Down 2.0%

NASDAQ:MDCX opened at $0.33 on Tuesday. Medicus Pharma has a 12-month low of $0.29 and a 12-month high of $8.94. The firm has a market capitalization of $13.07 million, a PE ratio of -0.12 and a beta of 1.16. The firm has a 50-day moving average price of $0.67 and a 200 day moving average price of $1.44.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.50). On average, research analysts expect that Medicus Pharma will post -0.56 EPS for the current year.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.